NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Safety and Efficacy of Lorbrena

CompletedN/A

Sponsor: Pfizer

Conditions: Non-small Cell Lung Cancer

Countries: Japan

To investigate the following matters under post-marketing use of Lorbrena in patients who received this drug 1. Factors affecting the onset of central nervous system disorder 2. Effect of Lorbrena in combination with CYP3A inducers on the onset of hepatic dysfunction

Eligibility overview

Sex: ALL

Age: 0 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* All administered patients

Exclusion Criteria:

* Nothing

Locations (1)

Tokyo, Japan